These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38197357)

  • 21. Mucormycosis: An opportunistic pathogen during COVID-19.
    Mahalaxmi I; Jayaramayya K; Venkatesan D; Subramaniam MD; Renu K; Vijayakumar P; Narayanasamy A; Gopalakrishnan AV; Kumar NS; Sivaprakash P; Sambasiva Rao KRS; Vellingiri B
    Environ Res; 2021 Oct; 201():111643. PubMed ID: 34237335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Online Registry of COVID-19-Associated Mucormycosis Cases, India, 2021.
    Arora S; Hemmige VS; Mandke C; Chansoria M; Rawat SK; Dravid A; Sethi Y; Medikeri G; Jariwala SP; Puius YA;
    Emerg Infect Dis; 2021; 27(11):2963-2965. PubMed ID: 34586056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Past, Present and Future of COVID-19 Associated Mucormycosis: A Rapid Review.
    Sarfraz Z; Sarfraz A; Jaiswal V; Poudel S; Bano S; Hanif M; Singh Shrestha P; Sarfraz M; Michel G; Cherrez-Ojeda I
    J Prim Care Community Health; 2022; 13():21501319221099476. PubMed ID: 35587142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucormycosis and Covid-19 : Risk Factors, Clinical Presentation and Outcome in a Tertiary Care Centre in North India.
    A GA; Ashraf H; HaiderMehdi HS
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Black fungus immunosuppressive epidemic with Covid-19 associated mucormycosis (zygomycosis): a clinical and diagnostic perspective from India.
    Singh K; Kumar S; Shastri S; Sudershan A; Mansotra V
    Immunogenetics; 2022 Apr; 74(2):197-206. PubMed ID: 34596728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The baneful alliance of COVID-19 and mucormycosis: Histopathological concerns.
    Singh A; Kumar V; Kumar V; Verma N
    Indian J Pathol Microbiol; 2023; 66(1):106-110. PubMed ID: 36656220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.
    Azhar A; Khan WH; Khan PA; Alhosaini K; Owais M; Ahmad A
    J Infect Public Health; 2022 Apr; 15(4):466-479. PubMed ID: 35216920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathological Study of Mucormycosis in Post COVID-19 Patients and Factors Affecting it in a Tertiary Care Hospital.
    Sree Lakshmi I; Kumari BS; Jyothi C; Devojee M; Padma Malini K; Sunethri P; Bheemrao Somalwar S; Kavitha T
    Int J Surg Pathol; 2023 Feb; 31(1):56-63. PubMed ID: 35668640
    [No Abstract]   [Full Text] [Related]  

  • 29. Pediatric Mucormycosis and COVID-19.
    Yadav S
    J Contemp Dent Pract; 2021 Aug; 22(8):855. PubMed ID: 34753834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucormycosis in renal transplant recipients: predictors and outcome.
    Godara SM; Kute VB; Goplani KR; Gumber MR; Gera DN; Shah PR; Vanikar AV; Trivedi HL
    Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):751-6. PubMed ID: 21743222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knowledge, attitude, and practice toward mucormycosis among patients discharged from a COVID-19 care tertiary center in South India: A questionnaire-based survey.
    Jayagayathri R; Ezhilvathani N; Venkatesh R
    Indian J Ophthalmol; 2023 Jul; 71(7):2818-2821. PubMed ID: 37417127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19-associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic's second wave in India.
    Aranjani JM; Manuel A; Abdul Razack HI; Mathew ST
    PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009921. PubMed ID: 34793455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence, cumulative mortality and factors affecting the outcome of COVID-19-associated mucormycosis from Western India.
    Vare AA; Yellambkar S; Farheen A; Nandedkar V; Bhombe SS; Shah R
    Indian J Ophthalmol; 2021 Dec; 69(12):3678-3683. PubMed ID: 34827021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucormycosis: An unanticipated progeny of COVID-19.
    Shrestha GS; Bhandari S; Lamsal R; Gurung U
    JNMA J Nepal Med Assoc; 2021 Sep; 59(241):965-967. PubMed ID: 35199723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 associated mucormycosis - An emerging threat.
    Chao CM; Lai CC; Yu WL
    J Microbiol Immunol Infect; 2022 Apr; 55(2):183-190. PubMed ID: 35074291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mass urine sugar testing to tackle post-COVID mucormycosis epidemic in India-MUSTARD concept.
    Garg P; Mittal S
    Diabetes Metab Syndr; 2021; 15(4):102177. PubMed ID: 34198108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics.
    Gupta G; S R; Singh Y; Thangavelu L; Singh SK; Dureja H; Chellappan DK; Dua K
    Drug Dev Res; 2021 Nov; 82(7):880-882. PubMed ID: 34323298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rhinocerebral Mucormycosis: An Emerging Threat in the Era of COVID-19.
    Maassarani D; Bassil GF; Nehme M; Nassar A; Ghanime G; Sleiman Z
    Cureus; 2022 Aug; 14(8):e28057. PubMed ID: 36127989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India.
    Wasiq M; K R; Gn A
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India.
    Joshi S; Telang R; Tambe M; Havaldar R; Sane M; Shaikh A; Roy C; Yathati K; Sonawale S; Borkar R; Magar R; Bhitkar H; Shitole S; Nakate L; Kudrimoti J; Mave V
    Emerg Infect Dis; 2022 Jan; 28(1):1-8. PubMed ID: 34586055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.